Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Background. Docetaxel (DOC) was the first regimen that increased the survival and became the standard-of-care in patients with metastatic castration-resistant prostate cancer (mCRPC). However, it is unclear whether switching to second-line chemotherapy or optimal sequencing of cabazitaxel (CBZ) ensu...

Full description

Bibliographic Details
Main Authors: Seiichi Kato, Manabu Takai, Koji Iinuma, Shota Fujimoto, Masahiro Nakano, Takashi Ishida, Masahiro Uno, Masayoshi Tamaki, Mitsuhiro Taniguchi, Hisao Komeda, Yoshito Takahashi, Takuya Koie
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1155/2021/8824140

Internet

http://dx.doi.org/10.1155/2021/8824140

Similar Items